Moneycontrol PRO
HomeNewsBusinessIndoco Remedies gets USFDA nod for schizophrenia, bipolar disorder treatment drug

Indoco Remedies gets USFDA nod for schizophrenia, bipolar disorder treatment drug

In a BSE filing, Indoco Remedies announced receipt of approval for its abbreviated new drug application (ANDA) for Olanzapine Tablets USP in the strengths of 2.5mg, 5mg, 7.5 mg, 10mg, 15mg and 20 mg.

August 06, 2020 / 11:18 IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Indoco Remedies on Thursday said it has received approval from the US health regulator for Olanzapine tablets, indicated for the treatment of schizophrenia and bipolar disorder. The approved product is therapeutically equivalent to the reference listed drug 'Zyprexa' of Eli Lilly.

In a BSE filing, Indoco Remedies announced receipt of approval for its abbreviated new drug application (ANDA) for Olanzapine Tablets USP in the strengths of 2.5mg, 5mg, 7.5 mg, 10mg, 15mg and 20 mg.

Quoting IMS data, Indoco Remedies said the US market size of Olanzapine tablets is USD 65 million.

Indoco Remedies Managing Director Aditi Kare Panandikar said this approval from the US health regulator will further supplement the solid dosage business for Indoco in the US.

Olanzapine is indicated for the treatment of schizophrenia and bipolar disorder. The drug may also be used in combination with other medication to treat depression and certain mental conditions.

Shares of Indoco Remedies were trading 1.67 percent higher at Rs 238.05 apiece on BSE.

PTI
first published: Aug 6, 2020 11:00 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347